StreetAlpha.app
Home › Stocks › DNA

Ginkgo Bioworks Holdings, Inc. (DNA)

Healthcare
$7.46
▼ −9.02%
LAST CLOSE · NOV 20

Ginkgo Bioworks provides cell engineering research services and biosecurity monitoring services to government and commercial customers. It last closed at $7.46 on Nov 20, down 9.02% on the day. The next earnings report for DNA is expected around Thu, Feb 25, 2027, after the close. For the quarter ended Sep 2026, DNA reported EPS of -$0.64 on revenue of $27.7M, with revenue down 5.7% from a year ago. Over its last 8 reports the stock moved an average of 15.3% the session after earnings. Over the last 12 months DNA insiders bought $0 of stock on the open market and sold $5.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is DNA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold DNA.

Key Stats

Last 12 months
Results
Revenue
$130.8M
−13.2% vs a year ago
Net income
−$251.0M
−192.0% margin
EPS (diluted)
−$4.17
Free cash flow
−$173.5M
−132.7% margin
Valuation
Market cap
$481.1M
64.5M shares
P/E
–
No P/E while losing money
Price to sales
3.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$84.5M
At Sep 30
Shareholder equity
$392.6M
Shares outstanding
64.5M
At Sep 30
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $313.8M$313.8MFY2021FY2022: $477.7M$477.7MFY2022FY2023: $251.5M$251.5MFY2023FY2024: $227.0M$227.0MFY2024FY2025: $170.2M$170.2MFY2025

From DNA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · After the close
Reported EPS
-$0.64
Quarter ended Sep 2026
Year ago EPS
-$1.45
Same quarter last year
Revenue
$27.7M
−5.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.96Dec '24Mar 2025: -$1.68Mar '25Jun 2025: -$1.10Jun '25Sep 2025: -$1.45Sep '25Dec 2025: -$1.42Dec '25Mar 2026: -$1.39Mar '26Jun 2026: -$0.75Jun '26Sep 2026: -$0.64Sep '26Latest -$0.64
Revenue by quarter
Dec 2024: $43.8MDec '24Mar 2025: $38.2MMar '25Jun 2025: $39.1MJun '25Sep 2025: $29.4MSep '25Dec 2025: $63.4MDec '25Mar 2026: $19.5MMar '26Jun 2026: $20.2MJun '26Sep 2026: $27.7MSep '26Latest $27.7M
How DNA moved after its last 8 reports
Average move the session after a report ±15.3%
Nov 5, 2026After the close+13.3%
Aug 5, 2026After the close−9.3%
May 7, 2026After the close−13.5%
Feb 26, 2026After the close−30.5%
Nov 6, 2025After the close−20.8%
Aug 7, 2025After the close−8.7%
May 6, 2025After the close+14.7%
Feb 25, 2025After the close−11.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on DNAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on DNA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on DNA

Technical Analysis

DNA · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 39% below its 20 day and 40% below its 50 day average. It is 16% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the swing low (Jul 28) at $7.22, and the nearest resistance the Pivot at $7.71.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 16.7%/day
Key levels
$18.2252 week high+144.2%
$10.4250 day average+39.7%
$10.3720 day average+39.0%
$9.13100 day average+22.4%
$8.63200 day average+15.7%
$8.04Pivot R1+7.8%
$7.75Swing high (Aug 19)+3.9%
$7.71Pivot+3.4%
$7.46Last close
$7.22Swing low (Jul 28)−3.2%
$7.13Pivot S1−4.4%
$5.3752 week low−28.0%
Indicators
RSI (14)36.92Weak, oversold below 30Neutral
MACD-0.68Below its signal lineBearish
Stochastic4.0Near the bottom of its rangeOversold
ADX (14)23.7Weak trend
Williams %R-98.6Oversold below −80, overbought above −20Oversold
CCI (20)-145.4Oversold below −100, overbought above 100Oversold
Rate of change−33.9%Change over 10 sessionsBearish
ATR (14)$1.25Typical daily range, 16.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for DNA

What happened before

See how DNA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow DNA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How DNA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for DNAHow many large options trades hit DNA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

DNA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●89 buying vs 80 selling
  • ▲Held by funds +4.5 pts
  • ●Funds holding -1
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding185186−0.5%
In funds' top 1023−33.3%
Held by funds60.7%56.1%+4.5 pts
New / increased30 / 5929 / 69−9.2%
Reduced / sold out48 / 3240 / 19+35.6%
Put/call ratio0.022.37−99.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DNA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

DNA Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$5.0M19 sales · 5 insiders
2025-12 sold $7K2026-01 sold $9K2026-03 sold $5K2026-04 sold $3.5M2026-05 sold $3K2026-07 sold $6K2026-08 sold $2K2026-09 sold $35K2026-10 sold $1.3MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 19Jason R KellySee remarksSale45,682$10.14$463K
Oct 19Reshma P. ShettySee remarksSale41,172$10.14$418K
Oct 19Barry Canton10% ownerSale41,172$10.14$418K
Oct 19Steven P. CoenSee remarksSale766$10.14$8K
Oct 5Steven P. CoenSee remarksSale2,403$15.00$36K
Sep 15Christian O HenryDirectorSale5,000$7.08$35K
Every insider buy and sale for DNA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See DNA insider trades →

From SEC Form 4 filings by DNA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DNA is in one of them and how their past DNA trades turned out.

DNA in the AI portfolios
Loading…

DNA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DNA in an article yet. Here's the latest on the wider market.

DNA in the news

About Ginkgo Bioworks Holdings

Ginkgo Bioworks is a biotechnology company based in Boston, Massachusetts. It sells services to government and commercial customers in two areas. In cell engineering, it provides biological research services and lab tools to companies that develop medicines, vaccines, food, and industrial products. In biosecurity, it helps governments monitor and detect biological threats, using genomic data collected at sites such as airports and border checkpoints.

Headquarters
Boston, MA
Founded
2008